Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Ulcerative colitis (UC) is a chronic, relapsing, remitting, and inflammatory disorder that afflicts millions of people around the world. It carries a substantial economic burden, reducing the quality of life, ability to work, and increasing disability. Conventional medical treatment of UC includes the use of aminosalicylates, corticosteroids, and immunosuppressive drugs. However, these medicines are not always effective due to some serious side effects. Nuclear factor-kappa B (NF-κB) is a key factor in the inflammatory setting and strongly affects the course of mucosal inflammation in UC. This review aims to describe the complex role of NF-κB in UC and discuss existing pharmacological attempts by curcumin for blocking NF-κB activation to develop new therapeutic strategies in UC. Several studies have shown intriguing pharmacologic effects associated with curcumin, which inhibits NF-κB expression by regulating NF-κB/IkB pathway and down-regulation expression of pro-inflammatory cytokines, such as Interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-α. The efficacy of curcumin has been confirmed in several experimental models of UC. Furthermore, curcumin significantly induced clinical remission in active mild-to-moderate UC patients and reduced clinical relapse in quiescent UC patients. The inhibitory effects of curcumin on NF-κB and its unrivaled safety profile indicate that it remains effective for the treatment of UC. In addition, curcumin is a nontoxic, inexpensive, and easily available natural polyphenol. In conclusion, curcumin can be used as a potential and safe drug in the management of patients with remission and mild-to-moderate UC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
The two NF-κB activation pathways and their role in innate and adaptive immunity
Bonizzi, G., & Karin, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.008 · Cited by 2,535
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548 · cited 2×
“The mainstay of treatment for patients with mild-to-moderate UC is mesalamine drugs, which can be administered orally or topically or in a combination thereof [74].”
BackgroundGreten, F. R., Arkan, M. C., Bollrath, J., Hsu, L.-C., Goode, J., Miething, C., Göktuna, S. I., Neuenhahn, M., Fierer, J., Paxian, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.009 · Cited by 616
Reimund, J. M., Wittersheim, C., Dumont, S., Muller, C. D., Baumann, R., Poindron, P., & Duclos, B. (1996) · Journal of Clinical Immunology · doi:10.1007/bf01540912 · Cited by 281
Clinical development of curcumin in neurodegenerative disease
Hu, S., Maiti, P., Ma, Q., Zuo, X., Jones, M. R., Cole, G. M., & Frautschy, S. A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1044981 · Cited by 179 · cited 1×
“One gram of turmeric can yield 60–200mg of curcumin [26].”
BackgroundAn analysis of 10218 ulcerative colitis cases in China
Jiang, X.-L. (2002) · World Journal of Gastroenterology · doi:10.3748/wjg.v8.i1.158 · Cited by 177
Cited by
Peng, Y., Ao, M., Dong, B., Jiang, Y., Yu, L., Chen, Z., Hu, C., & Xu, R. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s327378 · Cited by 827
Zhu, Y., Ouyang, Z., Du, H., Wang, M., Wang, J., Sun, H., Kong, L., Xu, Q., Ma, H., & Sun, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.022 · Cited by 414
Gao, W., Wang, C., Yu, L., Sheng, T., Wu, Z., Wang, X., Zhang, D., Lin, Y., & Gong, Y. (2019) · BioMed Research International · doi:10.1155/2019/6769789 · Cited by 220
Yin, J., Wei, L., Wang, N., Li, X., & Miao, M. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115041 · Cited by 45
Metadata
- Authors
- Wang, Y., Tang, Q., Duan, P., & Yang, L.
- Venue
- Immunopharmacology and Immunotoxicology
- Publisher
- Informa UK Limited
- Published
- 2018-08-15
- Volume
- 40
- Issue
- 6
- Pages
- 476-482
- ISSN
- 0892-3973 (ISSN-L)
- 1532-2513
- OpenAlex
- W2887132221
- Cited by
- 112
- References
- 8
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis. https://app.cochat.ai/papers/10.1080/08923973.2018.1469145
- The paper
- Wang, Y., Tang, Q., Duan, P., & Yang, L. (2018). Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis. Immunopharmacology and Immunotoxicology. https://doi.org/10.1080/08923973.2018.1469145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.